2 citations
,
May 2023 in “Journal of Advanced Research” In this study, researchers identified two genetic mutations associated with producing finer and denser wool in fine-wool sheep, involving the genes KRT74 and EDAR, which may guide future breeding efforts to enhance wool quality.
November 2020 in “Dubai medical journal” This case report described a 24-year-old with alopecia totalis who saw full scalp hair regrowth by the 9th month while using oral tofacitinib, which was well-tolerated and did not show serious adverse effects. Longer-term studies are needed to confirm its overall effectiveness for alopecia totalis.
January 2005 in “Jukuri (Natural Resources Institute Finland (Luke))” This study found that lower dietary protein with supplemented methionine allowed blue foxes to grow normally and produce high-quality pelts while reducing feed costs and environmental phosphorus and nitrogen loads.
67 citations
,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” This review discusses telogen effluvium, a common type of hair loss, focusing on differentiation from other conditions and potential causes, but presents no new research findings.
January 2022 in “Kafkas Universitesi Veteriner Fakultesi Dergisi” In this study, differences in protein expression related to twin lambing were identified in Tibetan sheep, providing insights into the reproductive performance and fertility improvement strategy for sheep in the Qinghai-Tibet Plateau.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
November 2025 in “Mendeley Data” In this study, tofacitinib and baricitinib showed comparable efficacy and tolerability under unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe alopecia areata over 24 weeks; however, the unorthodox baricitinib regimen yielded a lower effectiveness in severe cases, emphasizing the importance of adherence to guideline-recommended dosing.
April 2026 in “Clinical and Translational Science” In this multi-center, retrospective cohort study, researchers found that tofacitinib significantly reduced SALT scores and improved eyebrow and eyelash regrowth in patients with refractory alopecia areata after 12 weeks, with greater efficacy observed in severe cases and consistent results across pediatric and adult populations.
1 citations
,
January 2024 in “Asian Journal of Microbiology Biotechnology and Environmental Sciences” This review examines the growing global demand for diverse tea products, highlighting their health benefits and the economic challenges tea-producing countries face, while also exploring the rise of tea-based nutraceuticals, confectionery, toiletries, and cosmeceuticals.
In this study, women with acute telogen effluvium taking the Hair’InsideTM supplement for 84 days showed significant improvements in hair regrowth, shedding, brightness, and volume compared to placebo, with no reported adverse effects.
1 citations
,
February 2023 in “Animals” In this study, the inclusion of a feedstuff high in energy along with soybean meal enhanced body condition, body mass index, and reproductive performance in sheep fed low-protein forage.
July 2014 in “Americanae (AECID Library)” This study found that extracts from Tridax procumbens and Ouratea spectabilis reduced seed germination and inhibited root and hypocotyl growth in lettuce, indicating potential allelopathic effects.
May 2025 in “Journal of Pharmacy And Bioallied Sciences” In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.
March 2014 in “Journal of The American Academy of Dermatology” Vitamin D deficiency is common in temporary hair loss, and stress is often a suspected cause.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” This review summarizes findings on the long-term use of tofacitinib for severe alopecia areata, reporting its potential as a promising treatment option.
April 2024 in “Benha Medical Journal” In this study, patients with telogen effluvium had significantly lower levels of haemoglobin, hematocrit, and serum ferritin compared to healthy controls.
June 2024 in “Al- Anbar Medical Journal” This review discusses the mechanisms, causes, and treatment options for telogen effluvium, noting acute cases often resolve by addressing causative factors, while chronic forms remain challenging to treat; recent causes include post-hair transplantation, vitamin D deficiency, and COVID-19.
January 2015 in “Farmatsevtychnyĭ zhurnal” This research discusses the development of a complex tincture for telogen effluvium using nettle, sage, and chestnut leaves, but provides no new clinical results.
1 citations
,
December 2025 in “Journal of the American Academy of Dermatology”
October 2025 in “Brazilian Journal of Hair Health” This narrative review identifies telogen effluvium as a growing concern linked to weight-loss interventions, such as GLP-1 receptor agonists and bariatric surgery, attributing hair loss to systemic and metabolic stress rather than permanent hair follicle damage.
58 citations
,
March 2019 in “Frontiers in Pharmacology” This study found that wedelolactone from Eclipta prostrata L. significantly reduced lung inflammation and fibrosis in mice with bleomycin-induced pulmonary fibrosis, suggesting potential therapeutic benefits through AMPK activation.
August 2025 in “European Journal of Dermatology” This study found that patients with telogen effluvium experienced higher stress, depression, anxiety, and lower quality of life compared to healthy controls.
July 2026 in “Journal of the Kenya National Commission for UNESCO” In this study, commercial synthetic braiding hair samples from Kenya were analyzed, revealing that while no Ammonium Thioglycolate was detected, significant formaldehyde contamination was present, with varying concentrations throughout the hair strands, potentially impacting consumer safety.
April 2019 in “Agriculture and natural resources” January 2024 in “Dermatologic Therapy” This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.
11 citations
,
January 1987 in “Australian Journal of Experimental Agriculture” In this study, Australian cashmere goats receiving protein supplements maintained their weight and showed increased fleece growth, though cashmere growth was largely unaffected.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.
2 citations
,
November 2023 in “Acta dermato-venereologica” This study involving 126 patients found that tofacitinib has high effectiveness and an acceptable safety profile for treating alopecia areata, with a 33.8% complete response rate at 24 weeks and sex as an independent risk factor for outcomes.
January 2017 in “Egyptian Journal of Dermatology and Venereology” This study found that iron deficiency might play a role in the development of telogen effluvium in premenopausal women, highlighting the importance of checking hemoglobin in acute TE and serum ferritin in chronic TE.
April 2016 in “Journal of The American Academy of Dermatology” A vitamin and mineral supplement significantly reduced hair shedding in Brazilian women with telogen effluvium.